Log in to search using one of your social media accounts:

 

Correspondence Fighting drug-resistant tuberculosis in eastern Europe

We read with great interest the letter from Tomasz Jagielsi and colleagues1 presenting the Fight Against TB in Central and Eastern Europe (FATE). As the authors point out, eastern Europe is a hotspot for drug-resistant tuberculosis involving countries both within and outside the EU. The correspondence rightly highlights the need for intercountry and regional collaboration; however, it does not mention the existing regional initiatives and networks including WHO's European TB Laboratory Initiative (ELI),2 the Regional Collaborating Committee on TB,3 the European Centers for Disease Prevention and Control (ECDC) networks,4 and professional societies, among others.
Source: The Lancet Infectious Diseases - Category: Infectious Diseases Authors: Tags: Correspondence Source Type: research

Related Links:

Jesus Gonzalo-Asensio, Dessislava Marinova, Carlos Martin, Nacho Aguilo
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractBackgroundPatients ’ beliefs are a major factor affecting tuberculosis (TB) treatment adherence. However, there has been little use of Health Belief Model (HBM) in determining the pathway effect of patients’ sociodemographic characteristics and beliefs on TB treatment adherence. Therefore, this study was aimed at determining the effect of sociodemographic characteristics and patients’ health beliefs on TB treatment adherence based on the HBM concept in Ethiopia.MethodsA cross-sectional study was conducted in Addis Ababa, Ethiopia among TB patients undertaking treatment. Thirty health centres were ...
Source: Infectious Diseases of Poverty - Category: Infectious Diseases Source Type: research
CONCLUSIONS: In this paper, we describe the importance and implementation of USFDA's tentative approval process to review ARVs for resource-constrained settings. We also highlight the impact of patents and exclusivities on review of HIV drugs under tFDA and illustrate the concepts using a new HIV drug as an example. PMID: 29232052 [PubMed - in process]
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Source Type: news
CONCLUSION: The tubercular hypophysitis, as a result of performed tests, is discussed hereby, in the case report. PMID: 29232189 [PubMed - in process]
Source: Endocrine Regulations - Category: Endocrinology Tags: Endocr Regul Source Type: research
We report a case of HIV-associated opsoclonus-myoclonus and early HIV infection. A review of published literature shows opsoclonus-myoclonus can occur during early infection, in immune reconstitution syndrome or in association with other infections, especially tuberculosis.
Source: Journal of NeuroVirology - Category: Neurology Source Type: research
This study has been funded by King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia under the National Science, Technology and Innovation Plan (NSTIP: Grant#11-BIO-1436-20)’.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Corrigendum Source Type: research
ConclusionsSwitching from the standard Xpert cartridge to the Xpert Ultra cartridge for diagnosis of adult pulmonary TB may have different consequences in different clinical settings. In settings with high TB and HIV prevalence, Xpert Ultra is likely to offer considerable mortality benefit, whereas in lower-prevalence settings, Xpert Ultra will likely result in considerable overtreatment unless the possibility of higher specificity of Ultra in lower-prevalence settings in confirmed. The ideal use of the Ultra cartridge may therefore involve a more nuanced, setting-specific approach to implementation, with priority given to...
Source: PLoS Medicine - Category: Internal Medicine Authors: Source Type: research
For the first time, a urine test has been developed that reliably detects tuberculosis – a valuable weapon in the fight against an infection that kills millions
Source: New Scientist - Health - Category: Consumer Health News Source Type: research
European Union, European Centre for Disease Prevention and Control. 11/13/2017 This 228-page report presents the results of the zoonoses monitoring activities carried out in 2016 in 37 European countries (28 Member States [MS] and nine non-MS). It summarizes trends and sources for Yersinia (plague) and tularemia, both Category A bioterrorism agents; brucella, a Category B bioterrorism Agent; bovine tuberculosis, trichinellosis, echinococcosis, toxoplasmosis, rabies, Q fever, and West Nile fever. (PDF)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Authors: Source Type: news
More News: Infectious Diseases | Laboratory Medicine | Men | Tuberculosis